HK1040249B - 被雜環化合物取代的丙醇胺衍生物、其製備方法、含有所述化合物的藥物組合物及其用途 - Google Patents

被雜環化合物取代的丙醇胺衍生物、其製備方法、含有所述化合物的藥物組合物及其用途 Download PDF

Info

Publication number
HK1040249B
HK1040249B HK02102007.5A HK02102007A HK1040249B HK 1040249 B HK1040249 B HK 1040249B HK 02102007 A HK02102007 A HK 02102007A HK 1040249 B HK1040249 B HK 1040249B
Authority
HK
Hong Kong
Prior art keywords
alkyl
compounds
compound
phenyl
medicament
Prior art date
Application number
HK02102007.5A
Other languages
English (en)
Chinese (zh)
Other versions
HK1040249A1 (en
Inventor
W‧弗里克
W‧弗裏克
R‧基尔希
H‧格罗姆毕克
R‧基爾希
H‧霍耶尔
H‧格羅姆畢克
H‧霍耶爾
Original Assignee
萨诺费-阿文蒂斯德国有限公司
薩諾費-阿文蒂斯德國有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 萨诺费-阿文蒂斯德国有限公司, 薩諾費-阿文蒂斯德國有限公司 filed Critical 萨诺费-阿文蒂斯德国有限公司
Publication of HK1040249A1 publication Critical patent/HK1040249A1/xx
Publication of HK1040249B publication Critical patent/HK1040249B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK02102007.5A 1998-10-02 1999-09-18 被雜環化合物取代的丙醇胺衍生物、其製備方法、含有所述化合物的藥物組合物及其用途 HK1040249B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19845402.3 1998-10-02
DE19845402A DE19845402B4 (de) 1998-10-02 1998-10-02 Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP1999/006932 WO2000020410A1 (de) 1998-10-02 1999-09-18 Mit heterocyclen substituierte propanolaminderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number Publication Date
HK1040249A1 HK1040249A1 (en) 2002-05-31
HK1040249B true HK1040249B (zh) 2005-04-01

Family

ID=7883184

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102007.5A HK1040249B (zh) 1998-10-02 1999-09-18 被雜環化合物取代的丙醇胺衍生物、其製備方法、含有所述化合物的藥物組合物及其用途

Country Status (21)

Country Link
US (1) US6303639B1 (cg-RX-API-DMAC7.html)
EP (1) EP1117661B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002526539A (cg-RX-API-DMAC7.html)
KR (1) KR100611030B1 (cg-RX-API-DMAC7.html)
CN (1) CN1150185C (cg-RX-API-DMAC7.html)
AR (1) AR021843A1 (cg-RX-API-DMAC7.html)
AT (1) ATE267825T1 (cg-RX-API-DMAC7.html)
AU (1) AU760412B2 (cg-RX-API-DMAC7.html)
BR (1) BR9914266A (cg-RX-API-DMAC7.html)
CA (1) CA2346083A1 (cg-RX-API-DMAC7.html)
DE (2) DE19845402B4 (cg-RX-API-DMAC7.html)
DK (1) DK1117661T3 (cg-RX-API-DMAC7.html)
ES (1) ES2219065T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040249B (cg-RX-API-DMAC7.html)
HU (1) HUP0103893A3 (cg-RX-API-DMAC7.html)
PL (1) PL347105A1 (cg-RX-API-DMAC7.html)
PT (1) PT1117661E (cg-RX-API-DMAC7.html)
RU (1) RU2219176C2 (cg-RX-API-DMAC7.html)
TR (1) TR200100895T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000020410A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200102589B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CA2431995A1 (en) 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP2005505538A (ja) * 2001-08-22 2005-02-24 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アリール置換プロパノールアミン誘導体と他の活性成分との組み合わせ物およびその使用
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
RU2363699C2 (ru) * 2005-02-28 2009-08-10 Джапан Тобакко Инк. Новое производное аминопиридина с ингибиторной активностью в отношении syk.
US20130137728A1 (en) * 2010-03-24 2013-05-30 MUSC Foundation for Research and Development Compositions and Methods for the Treatment of Degenerative Diseases
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
US11238759B1 (en) 2015-10-29 2022-02-01 Ward-Kraft, Inc. Single ply wristband with printable coating
US11232719B1 (en) 2019-09-04 2022-01-25 Ward-Kraft, Inc. Single ply wristband with printable coating
EP4424363B1 (en) 2019-02-12 2026-04-29 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
USD988404S1 (en) 2020-02-14 2023-06-06 Rekon, Llc Wristband label form with single strap wristbands
USD941917S1 (en) 2020-02-18 2022-01-25 Ward-Kraft, Inc. Combination wristband label form with extender
USD967253S1 (en) 2020-02-26 2022-10-18 Ward-Kraft, Inc. Wristband form with extender

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1194273A3 (ru) * 1981-02-09 1985-11-23 Пфайзер Инк (Фирма) Способ получени пирбутерола или его аналогов
FI892341L (fi) * 1988-06-10 1989-12-11 Hoffmann La Roche Propanolaminderivat.
DE19704243A1 (de) * 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
ATE268758T1 (de) 1997-04-04 2004-06-15 Aventis Pharma Gmbh Hypolipidämische propanolaminderivate

Also Published As

Publication number Publication date
US6303639B1 (en) 2001-10-16
DK1117661T3 (da) 2004-08-30
AU6192599A (en) 2000-04-26
HK1040249A1 (en) 2002-05-31
PL347105A1 (en) 2002-03-25
EP1117661B1 (de) 2004-05-26
WO2000020410A1 (de) 2000-04-13
DE59909609D1 (de) 2004-07-01
EP1117661A1 (de) 2001-07-25
JP2002526539A (ja) 2002-08-20
TR200100895T2 (tr) 2001-12-21
HUP0103893A2 (hu) 2002-05-29
ES2219065T3 (es) 2004-11-16
CN1321154A (zh) 2001-11-07
HUP0103893A3 (en) 2002-10-28
ZA200102589B (en) 2002-02-27
DE19845402A1 (de) 2000-04-13
CN1150185C (zh) 2004-05-19
KR20010103593A (ko) 2001-11-23
BR9914266A (pt) 2001-11-06
DE19845402B4 (de) 2005-04-07
KR100611030B1 (ko) 2006-08-10
RU2219176C2 (ru) 2003-12-20
CA2346083A1 (en) 2000-04-13
ATE267825T1 (de) 2004-06-15
PT1117661E (pt) 2004-09-30
AU760412B2 (en) 2003-05-15
AR021843A1 (es) 2002-08-07

Similar Documents

Publication Publication Date Title
CN1150185C (zh) 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途
CN1135223C (zh) 芳基取代的丙醇胺衍生物、包含它们的药物和它们的用途
CN1145619C (zh) 1,4-苯并硫杂吖庚因衍生物、其制备方法、含有该化合物的药物及其用途
JP6602311B2 (ja) B型肝炎コアタンパク質アロステリックモジュレーター
CN1136193C (zh) 酰胺衍生物或其盐类
CN1882581A (zh) N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
CN1360591A (zh) 具有麻醉剂活性的3α-羟基-3β-甲氧基甲基-21-杂环取代的类固醇
CN1195747C (zh) 8,8a-二氢茚并[1,2-d]噻唑衍生物、它们的制备方法和制药用途
CN1065459A (zh) 哌啶衍生物及其制备方法和治疗应用
HK1052515B (zh) 在2-位携带具有磺酰胺结构或碸结构的取代基的8,8a-二氢茚并[1,2-d]噻唑衍生物、它们的制备方法和它们作为药物的用途
CN1199731A (zh) 丙醇胺衍生物、其方法、含有它们的药物组合物和其用途
BRPI0615102A2 (pt) composto, composições farmacêuticas como inibidores de dipeptidil peptidase-iv (dpp-iv), bem como uso
CN1141940C (zh) 多环噻唑体系用于制备预防或治疗肥胖的药物的用途
CN1148362C (zh) 多环的2-氨基噻唑体系、它们的制备方法和包含这些化合物的药物
CN1064865A (zh) 4-[(2-苯并噻唑基)甲氨基]-a-[(3,4-二氟苯氧基)甲基]-1-哌啶乙醇
HK1045809A1 (en) Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity
CN1149205C (zh) 多环的噻唑体系和它们作为减食欲剂的用途
CN1128798C (zh) 具有药物活性的三环胺类
KR101118574B1 (ko) 당뇨병 및 지질 질환 치료용 크로만 카르복시 산 유도체
CN1125065C (zh) 苯并[g]喹啉衍生物
CN1312809A (zh) N-取代的氮杂二环庚烷衍生物及其制备方法和用途
CN1443186A (zh) 用于糖尿病治疗的噻唑烷二酮盐
CN120230086A (zh) 苯并咪唑类化合物、其制备方法、组合物及其用途
CN1159306C (zh) 取代的8,8a-二氢-3aH-茚并[1,2-d]噻唑、它们的制备方法和它们作为药物的用途
CN1088922A (zh) 苯并喹喔啉

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080918